Phenytoin sodium Chemical Properties

storage temp. 

Inert atmosphere,Room Temperature

solubility 

aqueous base: soluble

form 

Crystalline Powder

color 

White to almost white

Merck 

14,7322

BCS Class

2

Stability:

Hygroscopic

InChIKey

FJPYVLNWWICYDW-UHFFFAOYSA-M

CAS DataBase Reference

630-93-3(CAS DataBase Reference)

EPA Substance Registry System

Diphenylhydantoin sodium (630-93-3)

Safety Information

Hazard Codes 

Xn

Risk Statements 

22-43-62-63

Safety Statements 

22-36/37/39-45

RIDADR 

UN 2811 6.1/PG 3

WGK Germany 

3

RTECS 

MU1400000

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

29332100

Toxicity

LD50 orally in mice: 490 mg/kg (Fink, Swinyard)

MSDS

• Language:English Provider:5,5-Diphenylhydantoin sodium salt
• Language:English Provider:SigmaAldrich

Phenytoin sodium Usage And Synthesis

Chemical Properties

White or almost white, crystalline powder, slightly hygroscopic.

Uses

antibacterial

Uses

Antiepileptic

Uses

5,5-Diphenylhydantoin sodium salt has been used:

• in the cream preparation for treating burn wounds
• in seizure behavior testing as an anticonvulsant in Drosophila
• in in vivo embryo toxicity test in mouse embryonic stem cells

brand name

Diphenylan (Lannett); Phenytek (Mylan); Phenytex (Watson) [Name previously used: Diphenylhydantoin Sodium.].

General Description

Phenytoin sodium, 5,5-diphenyl-2,4-imidazolidinedione, 5,5-diphenylhydantoin,diphenyl-hydantoin sodium (Dilantin), has been used fordecades in the control of grand mal types of epilepticseizure. It is structurally analogous to the barbiturates butdoes not possess their extensive sedative properties. Thecompound is available as the sodium salt. Solutions for parenteraladministration contain 40% propylene glycol and10% alcohol to dissolve the sodium salt.

Clinical Use

Phenytoin sodium’s cardiovascular effects were uncoveredduring observation of toxic manifestations of the drugin patients being treated for seizure disorders. Phenytoinsodium was found to cause bradycardia, prolong the PRinterval, and produce T-wave abnormalities on electrocardiograms.It is a class IB antiarrhythmic agent. Today,phenytoin sodium’s greatest clinical use as an antiarrhythmicdrug is in the treatment of digitalis-induced arrhythmias.34 Its action is similar to that of lidocaine. It depressesventricular automaticity produced by digitalis, without adverseintraventricular conduction. Because it also reversesthe prolongation of AV conduction by digitalis, phenytoinsodium is useful in supraventricular tachycardias caused bydigitalis intoxication.

Safety Profile

Confirmed carcinogen. Experimental teratogen. Other experimental reproductive effects. Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by ingestion: anorexia, respiratory depression, nausea or vomiting, hemorrhage, dermatitis, and endocrine effects. Mutation data reported. An anticonvulsant and cardiac depressant used for the treatment of grand mal and psychomotor seizures. When heated to decomposition it emits very toxic fumes of NOx and Na2O.

Carcinogenicity

Phenytoin and its sodium salt are reasonably anticipated to be human carcinogens based on sufficient evidence from studies in experimental animals.

Solubility in water

1 g dissolves in ca. 66 ml of water. The aqueous solution is turbid unless the pH is adjusted above 11.7, which is the pH of the saturated solution. 1 g dissolves in 10.5 mL of alcohol. Practically insoluble in ether and chloroform.

Phenytoin sodium(630-93-3)Related Product Information

• Sodium citrate
• Sodium hydroxide
• Sodium acetate
• Diphenylmethane
• Sodium chloride
• Sodium bicarbonate
• DIPHENYLCYCLOPROPENONE
• Chlorodiphenylphosphine
• Sodium benzoate
• Diphenylphosphine
• Imidazolidinyl urea
• Trisodium phosphate
• Sodium alginate
• tert-Butylchlorodiphenylsilane
• Biphenyl
• Diclofenac sodium
• 5,5-Diphenylhydantoin
• 8-CHLOROADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT